Buzzing Indian M&A/IPO Counter In 2016?
This article was originally published in Scrip
2016 could see an uptick in M&A deal flow in India and more than half a dozen healthcare/pharma firms may consider going public, buoyed by a clutch of successful recent IPOs, according to experts in the deal advisory/private equity space.
You may also be interested in...
Four key Asian markets witnessed nearly 200 life science company listings over the past 10 years, with China dominating the scene and expected to stay ahead, along with Hong Kong, for the foreseeable future. But India could prove a new contender over time as firms move up the value chain, a new report shows.
A recent round table on pharma industry trends has highlighted the hunger of cash-rich Indian firms for acquiring companies with niche portfolios in regulated markets including the US. Innovator companies shedding their generic units also present significant opportunities for Indian firms. Both trends are expected to build amid apparent Indian interest in the Teva-Allergan divestiture in Europe.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.